OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 100,000 Shares

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average price of $1.62 per share, with a total value of $162,000.00. Following the completion of the transaction, the chief executive officer now directly owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This represents a 0.05 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The stock was purchased at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

NASDAQ:OPK traded down $0.03 on Friday, reaching $1.59. 1,485,415 shares of the stock traded hands, compared to its average volume of 6,940,523. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The company’s fifty day simple moving average is $1.51 and its 200 day simple moving average is $1.43.

Analyst Ratings Changes

A number of analysts have recently weighed in on OPK shares. Piper Sandler reissued an “overweight” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Tuesday, September 17th. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th. Finally, StockNews.com raised OPKO Health to a “sell” rating in a research report on Saturday, July 27th.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently made changes to their positions in the company. CIBC Asset Management Inc grew its position in OPKO Health by 79.1% in the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 8,978 shares during the period. Hollencrest Capital Management grew its holdings in shares of OPKO Health by 14.0% in the second quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 11,020 shares during the period. FMR LLC increased its position in OPKO Health by 103.6% during the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 11,089 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in OPKO Health by 4.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock valued at $536,000 after acquiring an additional 17,671 shares during the period. Finally, Virtu Financial LLC purchased a new position in OPKO Health in the first quarter worth about $26,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.